Skip to main content

Advertisement

SpringerLink
Log in

Impact of PIN1 Inhibition on Tumor Progression and Chemotherapy Sensitivity in Colorectal Cancer

  • Original Research
  • Published:
Journal of Gastrointestinal Cancer Aims and scope Submit manuscript

Abstract

Background

Deregulated PIN1 is associated with cancer development and progression. Herein, for the first time, we evaluate the roles that PIN1 in tumorigenic characteristics of colorectal cancer (CRC) cells.

Methods

In this study, PIN1 expression was knocked down in SW-48 cells by synthetic small interfering RNA (siRNA). After confirming the knockdown of PIN1, cell viability, colony formation, apoptosis, autophagy, cancer stem cell (CSC)-related genes, CSC-related signaling pathways, cell migration, and 5-FU chemosensitivity were evaluated in vitro.

Results

Transfection of PIN1 siRNA into SW-48 cells inhibited cancer cell proliferation, migration, and increased apoptosis and autophagy. Transfected SW-48 cells had lower properties of CSCs through the inhibition of β-catenin and Notch1 gene expression. Moreover, inhibition of PIN1 enhanced the inhibitory effect of 5-FU on SW-48 cell proliferation.

Conclusion

Our results indicated that targeting of PIN1 serves as a promising therapeutic solution for the suppression of tumor progression processes in CRC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Yuan Y, Wang X, Chen G, Wang Y, Sheng W, Li X, et al. Updates in version 2019 of CSCO guidelines for colorectal cancer from version 2018. Chin J Cancer Res. 2019;31(3):423.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Dekker E, Tanis PJ, Vleugels JLA, Kasi PM, Wallace MB. Colorectal cancer. Lancet (London, England). 2019;394(10207):1467–80.

    Article  Google Scholar 

  3. Marie-Egyptienne DT, Lohse I, Hill RP. Cancer stem cells, the epithelial to mesenchymal transition (EMT) and radioresistance: potential role of hypoxia. Cancer Lett. 2013;341(1):63–72.

    Article  CAS  PubMed  Google Scholar 

  4. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell. 2007;1(5):555–67.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, et al. Identification and expansion of human colon-cancer-initiating cells. Nature. 2007;445(7123):111–5.

    Article  CAS  PubMed  Google Scholar 

  6. Jiang F, Qiu Q, Khanna A, Todd NW, Deepak J, Xing L, et al. Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer. Mol Cancer Res. 2009;7(3):330–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. van den Hoogen C, van der Horst G, Cheung H, Buijs JT, Lippitt JM, Guzmán-Ramírez N, et al. High aldehyde dehydrogenase activity identifies tumor-initiating and metastasis-initiating cells in human prostate cancer. Can Res. 2010;70(12):5163–73.

    Article  CAS  Google Scholar 

  8. Su YJ, Lai HM, Chang YW, Chen GY, Lee JL. Direct reprogramming of stem cell properties in colon cancer cells by CD44. The EMBO journal. 2011;30(15):3186–99.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Lim SH, Jang J, Park JO, Kim K-M, Kim ST, Park YS, et al. CD133-positive tumor cell content is a predictor of early recurrence in colorectal cancer. Journal of gastrointestinal oncology. 2014;5(6):447.

    PubMed  PubMed Central  Google Scholar 

  10. Takebe N, Ivy SP. Controversies in cancer stem cells: targeting embryonic signaling pathways. Clin Cancer Res. 2010;16(12):3106–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Zannini A, Rustighi A, Campaner E, Del Sal G. Oncogenic hijacking of the PIN1 signaling network. Front Oncol. 2019;9:94.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Hariharan N, Sussman MA. Pin1: a molecular orchestrator in the heart. Trends Cardiovasc Med. 2014;24(6):256–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Lu KP. Pinning down cell signaling, cancer and Alzheimer’s disease. Trends Biochem Sci. 2004;29(4):200–9.

    Article  CAS  PubMed  Google Scholar 

  14. Finn G, Luo M-L, Zhou XZ, Lu KP. Pin1: a promising novel diagnostic and therapeutic target that acts on numerous cancer-driving pathways. Atta-ur-Rahman, editor Sharjah, United Arab Emirates: Curr Cancer Drug Targets. 2013:146–71.

  15. Wulf GM, Ryo A, Wulf GG, Lee SW, Niu T, Petkova V, et al. Pin1 is overexpressed in breast cancer and cooperates with Ras signaling in increasing the transcriptional activity of c-Jun towards cyclin D1. The EMBO journal. 2001;20(13):3459–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Lian X, Lin Y-M, Kozono S, Herbert MK, Li X, Yuan X, et al. Pin1 inhibition exerts potent activity against acute myeloid leukemia through blocking multiple cancer-driving pathways. J Hematol Oncol. 2018;11(1):73.

  17. Tan X, Zhou F, Wan J, Hang J, Chen Z, Li B, et al. Pin1 expression contributes to lung cancer prognosis and carcinogenesis. Cancer Biol Ther. 2010;9(2):111–9.

    Article  CAS  PubMed  Google Scholar 

  18. Shi M, Chen L, Ji J, Cai Q, Yu Y, Liu B, et al. Pin1 is overexpressed and correlates with poor prognosis in gastric cancer. Cell Biochem Biophys. 2015;71(2):857–64.

    Article  CAS  PubMed  Google Scholar 

  19. Pyo J-S, Son BK, Oh IH. Cytoplasmic Pin1 expression is correlated with poor prognosis in colorectal cancer. Pathology-Research and Practice. 2018;214(11):1848–53.

    Article  CAS  PubMed  Google Scholar 

  20. Krishnan N, Titus MA, Thapar R. The prolyl isomerase pin1 regulates mRNA levels of genes with short half-lives by targeting specific RNA binding proteins. PLoS One. 2014;9(1).

  21. Khoei S, Mohammadi C, Mohammadi Y, Sameri S, Najafi R. Prognostic value of peptidyl-prolyl cis–trans isomerase 1 (PIN1) in human malignant tumors. Clin Transl Oncol. 2019:1–11.

  22. Luo M-L, Gong C, Chen C-H, Lee DY, Hu H, Huang P, et al. Prolyl isomerase Pin1 acts downstream of miR200c to promote cancer stem–like cell traits in breast cancer. Can Res. 2014;74(13):3603–16.

    Article  CAS  Google Scholar 

  23. Zhang Z-Z, Yu W-X, Zheng M, Liao X-H, Wang J-C, Yang D-Y, et al. PIN1 inhibition sensitizes chemotherapy in gastric cancer cells by targeting stem cell–like traits and multiple biomarkers. Mol Cancer Ther. 2020;19(3):906–19.

    Article  CAS  PubMed  Google Scholar 

  24. Ljvak K. Analysis of relative gene expression data using real time quantitative PCR and the 2^<-ΔΔCT> method. Methods. 2001;25:402–8.

    Article  CAS  Google Scholar 

  25. Saeednejad Zanjani L, Madjd Z, Rasti A, Asgari M, Abolhasani M, Tam KJ, et al. Spheroid-derived cells from renal adenocarcinoma have low telomerase activity and high stem-like and invasive characteristics. Frontiers in Oncology. 2019;9:1302.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Roudi R, Madjd Z, Ebrahimi M, Najafi A, Korourian A, Shariftabrizi A, et al. Evidence for embryonic stem-like signature and epithelial-mesenchymal transition features in the spheroid cells derived from lung adenocarcinoma. Tumor Biology. 2016;37(9):11843–59.

    Article  CAS  PubMed  Google Scholar 

  27. Lu Z, Hunter T. Prolyl isomerase Pin1 in cancer. Cell Res. 2014;24(9):1033–49.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Theuerkorn M, Fischer G, Schiene-Fischer C. Prolyl cis/trans isomerase signalling pathways in cancer. Curr Opin Pharmacol. 2011;11(4):281–7.

    Article  CAS  PubMed  Google Scholar 

  29. Kuramochi J, Arai T, Ikeda S, Kumagai J, Uetake H, Sugihara K. High Pin1 expression is associated with tumor progression in colorectal cancer. J Surg Oncol. 2006;94(2):155–60.

    Article  CAS  PubMed  Google Scholar 

  30. Kim C-J, Cho Y-G, Park Y-G, Nam S-W, Kim S-Y, Lee S-H, et al. Pin1 overexpression in colorectal cancer and its correlation with aberrant β-catenin expression. World J Gastroenterol: WJG. 2005;11(32):5006.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Zhou XZ, Lu KP. The isomerase PIN1 controls numerous cancer-driving pathways and is a unique drug target. Nat Rev Cancer. 2016;16(7):463.

    Article  CAS  PubMed  Google Scholar 

  32. Ayob AZ, Ramasamy TS. Cancer stem cells as key drivers of tumour progression. J Biomed Sci. 2018;25(1):20.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  33. Li X, Wang H, Ding J, Nie S, Wang L, Zhang L, et al. Celastrol strongly inhibits proliferation, migration and cancer stem cell properties through suppression of Pin1 in ovarian cancer cells. Eur J Pharmacol. 2019;842:146–56.

    Article  CAS  PubMed  Google Scholar 

  34. Roudi R, Barodabi M, Madjd Z, Roviello G, Corona SP, Panahi M. Expression patterns and clinical significance of the potential cancer stem cell markers OCT4 and NANOG in colorectal cancer patients. Mol Cell Oncol. 2020;7(5):1788366.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Vafaei S, Roudi R, Madjd Z, Aref AR, Ebrahimi M. Potential theranostics of circulating tumor cells and tumor-derived exosomes application in colorectal cancer. Cancer Cell Int. 2020;20(1):1–15.

    Article  CAS  Google Scholar 

  36. Sadeghi A, Roudi R, Mirzaei A, Zare Mirzaei A, Madjd Z, Abolhasani M. CD44 epithelial isoform inversely associates with invasive characteristics of colorectal cancer. Biomarkers in medicine. 2019;13(6):419–26.

    Article  CAS  PubMed  Google Scholar 

  37. Biddle A, Gammon L, Fazil B, Mackenzie IC. CD44 staining of cancer stem-like cells is influenced by down-regulation of CD44 variant isoforms and up-regulation of the standard CD44 isoform in the population of cells that have undergone epithelial-to-mesenchymal transition. PLoS ONE. 2013;8(2):e57314.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Phi LTH, Sari IN, Yang Y-G, Lee S-H, Jun N, Kim KS, et al. Cancer stem cells (CSCs) in drug resistance and their therapeutic implications in cancer treatment. Stem cells international. 2018;2018.

  39. Sánchez-Gundín J, Fernández-Carballido AM, Martínez-Valdivieso L, Barreda-Hernández D, Torres-Suárez AI. New trends in the therapeutic approach to metastatic colorectal cancer. Int J Med Sci. 2018;15(7):659.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  40. Ding Q, Huo L, Yang J-Y, Xia W, Wei Y, Liao Y, et al. Down-regulation of myeloid cell leukemia-1 through inhibiting Erk/Pin 1 pathway by sorafenib facilitates chemosensitization in breast cancer. Can Res. 2008;68(15):6109–17.

    Article  CAS  Google Scholar 

  41. Pannequin J, Joubert D, Hollande F. Intestinal Stem cells: From Homeostasis to Cancer. Stem Cells and Cancer Stem Cells, Volume 9: Springer; 2013. p. 219–26.

  42. Zhou Y, Xia L, Wang H, Oyang L, Su M, Liu Q, et al. Cancer stem cells in progression of colorectal cancer. Oncotarget. 2018;9(70):33403.

    Article  PubMed  Google Scholar 

  43. Rustighi A, Zannini A, Tiberi L, Sommaggio R, Piazza S, Sorrentino G, et al. Prolyl-isomerase Pin1 controls normal and cancer stem cells of the breast. EMBO Mol Med. 2014;6(1):99–119.

    Article  CAS  PubMed  Google Scholar 

  44. Ryo A, Nakamura M, Wulf G, Liou Y-C, Lu KP. Pin1 regulates turnover and subcellular localization of β-catenin by inhibiting its interaction with APC. Nat Cell Biol. 2001;3(9):793–801.

    Article  CAS  PubMed  Google Scholar 

  45. Ranganathan P, Weaver KL, Capobianco AJ. Notch signalling in solid tumours: a little bit of everything but not all the time. Nat Rev Cancer. 2011;11(5):338–51.

    Article  CAS  PubMed  Google Scholar 

  46. López-Sáez JF, De la Torre C, Pincheira J, Martín GG. Cell proliferation and cancer. Histol Histopathol. 1998;13(4):1197–214.

    PubMed  Google Scholar 

  47. Stukenberg PT, Kirschner MW. Pin1 acts catalytically to promote a conformational change in Cdc25. Mol Cell. 2001;7(5):1071–83.

    Article  CAS  PubMed  Google Scholar 

  48. Wulf GM, Liou Y-C, Ryo A, Lee SW, Lu KP. Role of Pin1 in the regulation of p53 stability and p21 transactivation, and cell cycle checkpoints in response to DNA damage. J Biol Chem. 2002;277(50):47976–9.

    Article  CAS  PubMed  Google Scholar 

  49. Tong Y, Ying H, Liu R, Li L, Bergholz J, Xiao Z. Pin1 inhibits PP2A-mediated Rb dephosphorylation in regulation of cell cycle and S-phase DNA damage. Cell Death Dis. 2015;6(2):e1640-e.

  50. Lin C-H, Li H-Y, Lee Y-C, Calkins MJ, Lee K-H, Yang C-N, et al. Landscape of Pin1 in the cell cycle. Exp Biol Med. 2015;240(3):403–8.

    Article  CAS  Google Scholar 

  51. Hongyu L, Hongling S, Qian X, Dongrui D, Shixuan W, Yunping L, et al. Expression of Pin1 and Ki67 in cervical cancer and their significance. J Huazhong Univ Sci Technolog Med Sci. 2006;26(1):120–2.

    Article  Google Scholar 

  52. Lv L, Zhou Z, Huang X, Zhao Y, Zhang L, Shi Y, et al. Inhibition of peptidyl–prolyl cis/trans isomerase Pin1 induces cell cycle arrest and apoptosis in vascular smooth muscle cells. Apoptosis. 2010;15(1):41.

    Article  CAS  PubMed  Google Scholar 

  53. Burada F, Nicoli ER, Ciurea ME, Uscatu DC, Ioana M, Gheonea DI. Autophagy in colorectal cancer: an important switch from physiology to pathology. World journal of gastrointestinal oncology. 2015;7(11):271.

    Article  PubMed  PubMed Central  Google Scholar 

  54. Gil J, Pesz KA, Sąsiadek MM. May autophagy be a novel biomarker and antitumor target in colorectal cancer? Biomark Med. 2016;10(10):1081–94.

    Article  CAS  PubMed  Google Scholar 

  55. Ku B, Woo J-S, Liang C, Lee K-H, Hong H-S, Xiaofei E, et al. Structural and biochemical bases for the inhibition of autophagy and apoptosis by viral BCL-2 of murine γ-herpesvirus 68. PLoS Pathog. 2008;4(2):e25.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  56. Li B-X, Li C-Y, Peng R-Q, Wu X-J, Wang H-Y, Wan D-S, et al. The expression of beclin 1 is associated with favorable prognosis in stage IIIB colon cancers. Autophagy. 2009;5(3):303–6.

    Article  PubMed  Google Scholar 

  57. Chen Z, Li Y, Zhang C, Yi H, Wu C, Wang J, et al. Downregulation of Beclin1 and impairment of autophagy in a small population of colorectal cancer. Dig Dis Sci. 2013;58(10):2887–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Namgoong GM, Khanal P, Cho H-G, Lim S-C, Oh YK, Kang BS, et al. The prolyl isomerase Pin1 induces LC-3 expression and mediates tamoxifen resistance in breast cancer. J Biol Chem. 2010;285(31):23829–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Wagenaar-Miller RA, Gorden L, Matrisian LM. Matrix metalloproteinases in colorectal cancer: is it worth talking about? Cancer Metastasis Rev. 2004;23(1–2):119–35.

    Article  CAS  PubMed  Google Scholar 

  60. Moran A, Iniesta P, Garcia-Aranda C, De Juan C, Diaz-Lopez A, Sanchez-Pernaute A, et al. Clinical relevance of MMP-9, MMP-2, TIMP-1 and TIMP-2 in colorectal cancer. Oncol Rep. 2005;13(1):115–20.

    CAS  PubMed  Google Scholar 

  61. Quintero-Fabián S, Arreola R, Becerril-Villanueva E, Torres-Romero JC, Arana-Argáez VE, Lara-Riegos J, et al. Role of Matrix Metalloproteinases in Angiogenesis and Cancer. Front Oncol. 2019;9:1370.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Funding

This study was funded by Hamadan University of Medical Sciences under grant number 9710256415.

Author information

Authors and Affiliations

  1. Research Center for Molecular Medicine, Hamadan University of Medical Sciences, Hamadan, Iran

    Saeideh Gholamzadeh Khoei, Massoud Saidijam, Razieh Amini, Akram Jalali & Rezvan Najafi

Authors
  1. Saeideh Gholamzadeh Khoei
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Massoud Saidijam
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Razieh Amini
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Akram Jalali
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Rezvan Najafi
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

All authors contributed to the study conception and design. All authors reviewed this draft, contributed and approved the final manuscript.

Corresponding author

Correspondence to Rezvan Najafi.

Ethics declarations

Consent for Publication

All the authors approved the version to be published and agreed to be accountable for all aspects of the work.

Competing Interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gholamzadeh Khoei, S., Saidijam, M., Amini, R. et al. Impact of PIN1 Inhibition on Tumor Progression and Chemotherapy Sensitivity in Colorectal Cancer. J Gastrointest Canc 53, 299–310 (2022). https://doi.org/10.1007/s12029-021-00600-6

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12029-021-00600-6

Keywords

Search

Navigation